NCT00975182

A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors

A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 58 (actual)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics (PK) of oral (PO) GDC-0941 administered in combination with PO erlotinib in patients with advanced solid tumors and patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have failed at least one prior chemotherapy regimen.

Conditions

• Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers

Interventions

Type	Name	Description
DRUG	GDC-0941	Oral repeating dose
DRUG	erlotinib HCl	Oral repeating dose

Timeline

• Start date: 2009-09-01
• Primary completion: 2014-09-01
• Completion: 2014-09-01
• First posted: 2009-09-11
• Last updated: 2016-11-02

Locations

4 sites across 2 countries: United States, Netherlands